Related Experiment Video

Updated: Jun 15, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Diabetogenic effect of two synthetic estrogens in force-fed, alloxandiabetic rats

D J INGLE, J A HOGG

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
    |March 19, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    Keywords:
    DIABETES, ALLOXAN/estrogenESTROGENE/diabetogenic effect

    More Related Videos

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies06:24

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

    Published on: January 10, 2025

    Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration06:51

    Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

    Published on: June 7, 2012

    Related Concept Videos

    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...